Inventor · disambiguated record
George Kindness
Also filed as: KINDNESS GEORGE
1 granted patent·8 pending applications·24 citations·filing 2001–2003
42Inventor score
Top patents by PatentIndex Score
9 records- 0180US6534540B2Combination and method of treatment of cancer utilizing a COX-2 inhibitor and a 3-hydroxy-3-methylglutaryl-coenzyme-a (HMG-CoA) reductase inhibitorFiled 2001·Granted Mar 18, 2003·24 cites·11 claims
- 0245US2003162829A1Combination of treatment of cancer utilizing a COX-2 inhibitor and a 3-hydroxy-3-methylglutaryl-coenzyme-a (HMG-CoA) reductase inhibitorFiled 2003·Application pending·0 cites
- 0344US2002034760A1Combination and method presenting and utilizing DNA analysis and for diagnosis and treatmentFiled 2001·Application pending·0 cites
- 0442US2002169195A1Combination and method of treatment of cancer utilizing a COX-2 inhibitor and an HMG-CoA inhibitor and cystine to enhance glutathioneFiled 2002·Application pending·0 cites
- 0542US2002137785A1Inflammatory mechanism modulator composition and methods with anti-asthmatic propertiesFiled 2002·Application pending·0 cites
- 0642US2002182585A1Combination and method using EDTA, cystine, zinc and selenium for anti-thrombin effect and for anti-platelet aggregation and measurement of efficacyFiled 2002·Application pending·0 cites
- 0741US2002132781A1Combination and method of treatment of cancer utilizing a COX-2 inhibitor and A 3-hydroxy-3-methylglutaryl-coenzyme-A (HMG-CoA) reductase inhibitorFiled 2001·Application pending·0 cites
- 0840US2002187130A1Adjuvant immune therapy in the treatment of solid tumors through modulation of signaling pathways following engagement of humoral and cell mediated responsesFiled 2001·Application pending·0 cites
- 0940US2004092565A1Composition and method of sustaining chemotherapeutic effect while reducing dose of chemotherapeutic agent using cox-2 inhibitor and statinFiled 2002·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when George Kindness files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →